• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » LivaNova wins FDA clearance, CE mark for Essenz in-line blood monitor

LivaNova wins FDA clearance, CE mark for Essenz in-line blood monitor

August 30, 2023 By Sean Whooley

LivaNova Essenz in-line blood monitor ILBM
The Essenz in-line blood monitor. [Image courtesy of LivaNova]
LivaNova (Nasdaq: LIVN) announced today that it received FDA 510(k) clearance and CE mark for its Essenz in-line blood monitor.

Essenz ILBM provides accurate and continuous measurement of essential blood parameters throughout cardiopulmonary bypass (CPB) procedures, according to LivaNova. It integrates into the next-generation Essenz perfusion system. Essenz enables perfusionists to access and manage reliable blood parameters directly from the system’s cockpit. It eliminates the need for additional monitors or holders.

London-based LivaNova says that existing blood-gas analyzers only reflect the patient’s clinical condition at the exact moment a sample is drawn. This sample can quickly change, and the analysis becomes irrelevant. Essenz ILBM provides in-line, continuous monitoring for the duration of a procedure. LivaNova said this allows for the delivery of a patient-tailored approach to perfusion rooted in data-driven decisions.

B-Capta sensing technology powers Essenz ILBM, enabling it to provide parameter values in line with hospital blood-gas analyzers. It provides measured values for oxygen saturation, hematocrit, partial pressure of oxygen and temperature. The alternative, LivaNova said, is calculated values for these parameters.

Essenz ILBM also requires no calibration to set device measurements, saving perfusionists time. Arterial and venous parameters automatically transfer to the Essenz patient monitor, supporting decision-making and goal-directed perfusion.

“Dynamic conditions can rapidly change a patient’s blood parameters during a cardiopulmonary bypass procedure,” said Marco Dolci, LivaNova president, cardiopulmonary. “The Essenz In-Line Blood Monitor provides continuous monitoring throughout a patient’s procedure. Access to accurate, real-time measurements directly from the Essenz perfusion system allows for quick decisions and tailored care strategies to serve the patient.”

Filed Under: 510(k), Blood Management, Cardiovascular, Food & Drug Administration (FDA), Health Technology, News Well, Regulatory/Compliance, Vascular Tagged With: LivaNova

More recent news

  • FDA warns of Philips ultrasound issues after four patient deaths
  • FDA approves Gore bridging stent graft in complex aortic aneurysms
  • Steris inks $2.1B deal for operating room supplier Xodus Medical
  • Insulet’s Omnipod Discover data platform begins full US rollout
  • Siemens Healthineers exits general ultrasound to focus on cardiac imaging

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy